Type 1 Diabetes The application of GLP-1 RAs in type 1 diabetes exemplifies precision medicine addressing specific patient phenotypes, with concomitant obesity common among patients and only 20% achieving adequate glycemic control
However, some people experience worsening side effects over time, including persistent nausea and digestive problems
Retinoid speeds up cellular turnover, removing the uppermost, most damaged, darker skin layers
Similar content being viewed by others Log in or create a free account to read this content Gain free access to this article, as well as selected content from this journal and more on nature.com or References Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al
This carefully calibrated receptor selectivity profile contributes to the favorable side effect profile observed in clinical studies, where gastrointestinal adverse events were predominantly mild and occurred mainly during dose escalation phases
Copyright 2012 Diabetes In Control, Inc.
